SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant volatility following its earnings release, as investors weigh a bottom-line profit beat against managements warnings of substantial increases in capital expenditures for AI and robotics ambitions. The community remains deeply divided, with many traders frustrated by the stock's after-hours reversal and management's shifting timelines, while long-term bulls continue to view the aggressive spending and focus on future-tech as a necessary foundation for long-term growth.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is capturing investor interest as traders draw parallels between its current chart structure and the recent high-volatility performance of other meme-basket stocks like Avis. Community discussion is buzzing with speculation about potential strategic acquisitions and the role of large-scale share positioning, while retail sentiment remains fixated on the possibility of a renewed squeeze driven by long-term holders and observed market patterns.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing extreme volatility and intense community debate as traders grapple with conflicting geopolitical headlines, suspicious after-hours price action, and persistent rumors of market manipulation. Investors remain sharply divided, with many debating whether the ongoing rally is fundamentally supported by earnings or if the market is being artificially propped up by algorithmic activity amid a tense global climate.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as investors remain divided over the sustainability of its persistent rally, fueled by bullish tech earnings and heavy algorithmic buying despite broader macroeconomic concerns like rising oil prices and geopolitical volatility. Community members are actively debating whether this movement represents a legitimate growth trend or a manipulated 'fake' market, with many traders closely watching major tech earnings and war-related headlines for signs of a potential reversal or continued upside.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as capital flows into cannabis names following reports that the U.S. administration is nearing a decision on marijuana reclassification. Investors are actively debating the potential for long-term reform, with the community focused on the impact of policy tailwinds versus historical volatility and management's past share dilution.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing a surge in investor interest and volatility ahead of its earnings report, driven by optimism over the company's expansion into AI data center infrastructure and defense applications. The community is actively debating the company's long-term commercialization progress, with bulls highlighting the technological potential and OEM partnerships while bears remain skeptical of management's communication and the timeline to profitability.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense market volatility as investors aggressively unwind a massive short squeeze that sent shares to extreme highs. Community sentiment is deeply polarized, with many retail traders actively discussing whether the rapid decline represents a permanent crash or a potential setup for another volatile bounce.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors speculate on potential upcoming partnerships and a possible Coinbase listing, driving high social media activity and discussions regarding its long-term adoption. The community is actively debating the potential impact of major industry events, with many holders focused on accumulation as they wait for breakout signals.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant upward momentum driven by strong investor interest in its role within the AI data center power infrastructure, specifically through its GaN technology and ongoing partnerships. While bullish sentiment centers on the potential for long-term growth and supply chain importance, the community remains divided as traders debate the sustainability of the current valuation amid short squeeze dynamics and upcoming earnings.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a sharp, sentiment-driven sell-off sparked by concerns that AI coding tools could disrupt its legacy COBOL business, a narrative investors are now re-evaluating as a potential overreaction. The community is actively debating the stock's valuation and the company's competitive moat, with many long-term bulls highlighting recent defense contract wins and stable institutional support as reasons to view the price decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2026 EPS Estimates for Savara Decreased by Lifesci Capital

Savara Inc. (NASDAQ:SVRA - Free Report) - Lifesci Capital cut their FY2026 EPS estimates for shares of Savara in a research report issued on Thursday, April 16th. Lifesci Capital analyst F. Brisebois...

Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why

Savara (NASDAQ:SVRA) Trading Up 2.5% - Here's What Happened...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the...

<ul class="summary-bullets"><li>The company was looking for FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.</li><li>The company had submitted certain responses to the FDA recently which the agency determined represents a major amendment to the application, the company explained.</li><li>Savara added that the agency did not cite any safety, efficacy, or manufacturing concerns in their correspondence.</li></ul>Shares of Savara Inc. (SVRA) slumped as much as 4% after-hours on Wednesday after the company said that the U.S. Food and Drug Administration has extended the review time of its application seeking approval for its experimental therapy molgramostim by three months.The company was looking for the FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), a rare lung disease where autoantibodies block the clearing of surfactant in the lungs, causing a buildup that disrupts oxygen exchange, creating breathing difficulties, and chronic coughing.The agency is now slated to decide on the application by November 22, Savara said. The former deadline for a decision was August 22.<h2 class="st-heading-2">Why The Delay?</h2>The company had submitted certain responses to the FDA recently, which the agency determined represents a major amendment to the application, the company explained. The additional time will allow the agency time to review the extra materials submitted, it added.Savara added that the agency did not cite any safety, efficacy, or manufacturing concerns in its correspondence.Savara completed submission of its application to the FDA for molgramostim as a treatment for aPAP in March. It was granted priority review by the agency. &nbsp;According to Savara, molgramostim has the potential to be the first and only approved therapy for Autoimmune PAP.The company had previously submitted an application for the experimental therapy but received a “refuse to file” letter from the FDA in May 2025 due to insufficient Chemistry, Manufacturing, and Controls data. The company resubmitted the application, stating that Fujifilm Biotechnologies will manufacture the drug substance. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SVRA stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SVRA">SVRA stock</a> has more than doubled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-on-track-for-best-day-in-nearly-seven-months-ahead-of-q1-earnings/cZJtNmERIwY">TSLA Stock On Track For Best Day In Nearly 7 Months Ahead Of Q1 Earnings As Musk Hails AI5 Milestone</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Savara Inc. (SVRA) was looking for FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.

Equity

The agency is now slated to decide on the application by November 22, Savara said.


Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended the review period for the...

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS...

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the MHRA has accepted the submission of the MOLBREEVI...

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI...

Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Savara Inc. (NASDAQ:SVRA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports...

Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-31-savara-inc-stock...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.14	--	--	N/A
Q4 '25	-$0.12	-$0.13	-10.64%	MISSED
Q3 '25	-$0.13	-$0.14	-5.66%	MISSED
Q2 '25	-$0.12	-$0.14	-16.67%	MISSED
Q1 '25	-$0.13	-$0.12	4.55%	BEAT

SVRA
Savara Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SVRA News

SVRASavara Inc